NOVADEL PHARMA INC.
CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’
DEFICIENCY
FOR THE SIX MONTHS ENDED JUNE 30, 2010
(UNAUDITED)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares |
|
Amount |
|
Additional
Paid-In
Capital |
|
Accumulated
Deficit |
|
Treasury
Stock |
|
Total
Stockholders’
Deficiency |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, December 31, 2009 |
|
|
88,343,457 |
|
$ |
89,000 |
|
$ |
78,342,000 |
|
$ |
(82,766,000 |
) |
$ |
(6,000 |
) |
$ |
(4,341,000 |
) |
|
Share-based compensation expense |
|
|
— |
|
|
— |
|
|
323,000 |
|
|
— |
|
|
— |
|
|
323,000 |
|
|
Restricted stock cancelled |
|
|
(60,000 |
) |
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
|
Issuance of Common Stock |
|
|
10,100,001 |
|
|
10,000 |
|
|
591,000 |
|
|
— |
|
|
— |
|
|
601,000 |
|
|
Net loss |
|
|
— |
|
|
— |
|
|
— |
|
|
(2,418,000 |
) |
|
— |
|
|
(2,418,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, June 30, 2010 |
|
|
98,383,458 |
|
$ |
99,000 |
|
$ |
79,256,000 |
|
$ |
(85,184,000 |
) |
$ |
(6,000 |
) |
$ |
(5,835,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to
condensed financial statements.
F-31
|
F 888.329.6696